Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a ...

In this study, researchers aimed to compare the efficacy of zanidatamab-based combinations against the current standard of care in treatment-naïve, advanced, HER2+ gastric/GEJ cancer.

Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the combination of pembrolizumab and enfortumab vedotin for use both before ...

Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside the immunotherapy drug ...

Despite high OS rates in patients with resectable stage III melanoma, recurrence is common at 36 months of treatment with immunotherapy.

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study PD-1 immune checkpoint ...

Association of cell-free DNA dominant clone allele frequency with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy. This is an ASCO Meeting Abstract from the 2021 ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III ...

FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...

Pembrolizumab plus enfortumab vedotin is now approved for all adults with muscle-invasive bladder cancer undergoing cystectomy.

Merck’s blockbuster PD-1 inhibitor pembrolizumab (Keytruda) may be effective against endometrial cancer in some settings, but a statement today from the company shows that’s not so for all settings, ...